Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)

Rationale: Chronic cough remains a major and often debilitating symptom for patients with idiopathic pulmonary fibrosis (IPF). In a phase 2A study, inhaled RVT-1601 (cromolyn sodium) reduced daytime cough and 24-hour average cough counts in patients with IPF. Objectives: To determine the efficacy, safety, and optimal dose of inhaled RVT-1601 for the treatment of chronic cough in patients with IPF. Methods: In this multicenter, randomized, placebo-controlled phase 2B study, patients with IPF and chronic cough for

• Martinez, F. J.
• Wijsenbeek, M. S.
• Raghu, G.
• Flaherty, K. R.
• Maher, T. M.
• Wuyts, W. A.
• Kreuter, M.
• Kolb, M.
• Chambers, D. C.
• Fogarty, C.
• Mogulkoc, N.
• Tutuncu, A. S.
• Richeldi, L.